Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Harmony Biosciences Holdings, Inc.

NASDAQ: HRMY · Life Sciences · 5 alerts · CIK 1802665

Share price
$32.96Close, Nov 16
Market cap
$1.94B
Shares outstanding
58.72MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Harmony Biosciences Holdings, Inc. filings on SEC EDGAR ↗

8:16 AM ET 10-Q
Financial Results

Harmony Biosciences Holdings Q3 2026 Results: Net Income $48.2M, Down 5.2% YoY

Harmony Biosciences reported net product revenue of $268.9 million for the third quarter of 2026, a 12.3% increase year-over-year. Net income for the nine months ended September 30, 2026, rose to $156.1 million compared to $136.2 million in the prior year, despite higher operating expenses driven by research and development.

Key figure
Net income $48.2M · -5.2% YoY
8:01 AM ET 8-K
Financial Results

Harmony Biosciences Holdings Financial Results

Harmony Biosciences reported Q3 2026 financial results with WAKIX net revenue of $269 million, driven by 400 net patient additions. The company reaffirmed its full-year 2026 revenue guidance of $1.0 billion to $1.04 billion and announced that Peter Anastasiou will succeed Jeffrey Dayno as CEO effective January 1, 2027.

“As I prepare to transition the President and CEO role to Peter on January 1, I believe Harmony is operating from a position of strength, with a durable and growing WAKIX franchise, the financial flexibility to invest in innovation, conviction to pursue strategic business development opportunities, and a pipeline led by BP-205 that has the potential to generate significant long-term value.”

Jeffrey Dayno, MD, President and Chief Executive Officer

“I am proud of the talented team and passionate organization we have built, which position Harmony for continued success in delivering innovative treatments to patients and sustained value for our shareholders.”

Jeffrey Dayno, MD, President and Chief Executive Officer
4:15 PM ET 8-K/A
Executive Compensation

Harmony Biosciences Holdings Executive Compensation

Harmony Biosciences announced the compensation terms for its leadership succession plan, including a separation and consulting agreement for retiring CEO Jeffrey M. Dayno and an amended employment agreement for incoming CEO Peter Anastasiou. Dr. Dayno will serve as a non-executive advisor through January 2028 at a rate of $500 per hour with continued equity vesting, while Mr. Anastasiou's new terms as President and CEO take effect January 1, 2027.

Term
through Jan 2028

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.